289 related articles for article (PubMed ID: 29360950)
1. Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Zhang D; Prabhu VS; Marcella SW
Clin Infect Dis; 2018 Apr; 66(9):1326-1332. PubMed ID: 29360950
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
3. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
4. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
5. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Wilcox MH; Ahir H; Coia JE; Dodgson A; Hopkins S; Llewelyn MJ; Settle C; Mclain-Smith S; Marcella SW
J Antimicrob Chemother; 2017 Sep; 72(9):2647-2656. PubMed ID: 28633368
[TBL] [Abstract][Full Text] [Related]
6. Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.
Dinh A; Le Monnier A; Emery C; Alami S; Torreton É; Duburcq A; Barbier F
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1297-1305. PubMed ID: 30941532
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
Rodrigues R; Barber GE; Ananthakrishnan AN
Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.
Shah DN; Aitken SL; Barragan LF; Bozorgui S; Goddu S; Navarro ME; Xie Y; DuPont HL; Garey KW
J Hosp Infect; 2016 Jul; 93(3):286-9. PubMed ID: 27209056
[TBL] [Abstract][Full Text] [Related]
9. Attributable Cost of Clostridium difficile Infection in Pediatric Patients.
Mehrotra P; Jang J; Gidengil C; Sandora TJ
Infect Control Hosp Epidemiol; 2017 Dec; 38(12):1472-1477. PubMed ID: 29173236
[TBL] [Abstract][Full Text] [Related]
10. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study.
Antunes A; Tricotel A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
BMC Infect Dis; 2024 May; 24(1):548. PubMed ID: 38822244
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes.
Tresman R; Goldenberg SD
J Antimicrob Chemother; 2018 Oct; 73(10):2851-2855. PubMed ID: 29982502
[TBL] [Abstract][Full Text] [Related]
12. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study.
Yu H; Baser O; Wang L
BMC Geriatr; 2016 Nov; 16(1):193. PubMed ID: 27884118
[TBL] [Abstract][Full Text] [Related]
13. Attributable costs and length of stay of hospital-acquired
Leal JR; Conly J; Weaver R; Wick J; Henderson EA; Manns B; Ronksley P
Infect Control Hosp Epidemiol; 2019 Oct; 40(10):1135-1143. PubMed ID: 31342884
[TBL] [Abstract][Full Text] [Related]
14. Excess length of hospital stay, mortality and cost attributable to
Kimura T; Stanhope S; Sugitani T
Epidemiol Infect; 2020 Mar; 148():e65. PubMed ID: 32115019
[TBL] [Abstract][Full Text] [Related]
15. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals.
Le Monnier A; Duburcq A; Zahar JR; Corvec S; Guillard T; Cattoir V; Woerther PL; Fihman V; Lalande V; Jacquier H; Mizrahi A; Farfour E; Morand P; Marcadé G; Coulomb S; Torreton E; Fagnani F; Barbut F;
J Hosp Infect; 2015 Oct; 91(2):117-22. PubMed ID: 26253518
[TBL] [Abstract][Full Text] [Related]
16. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.
Gabriel L; Beriot-Mathiot A
J Hosp Infect; 2014 Sep; 88(1):12-21. PubMed ID: 24996516
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.
Desai K; Gupta SB; Dubberke ER; Prabhu VS; Browne C; Mast TC
BMC Infect Dis; 2016 Jun; 16():303. PubMed ID: 27316794
[TBL] [Abstract][Full Text] [Related]
18. Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016.
Mollard S; Lurienne L; Heimann SM; Bandinelli PA
J Hosp Infect; 2019 Jun; 102(2):135-140. PubMed ID: 30690052
[TBL] [Abstract][Full Text] [Related]
19. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.
Reveles KR; Yang M; Garcia-Horton V; Edwards ML; Guo A; Lodise T; Bochan M; Tillotson G; Dubberke ER
Adv Ther; 2023 Jul; 40(7):3104-3134. PubMed ID: 37210680
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Clostridium difficile infection in intensive care unit patients.
Jasiak NM; Alaniz C; Rao K; Veltman K; Nagel JL
Am J Infect Control; 2016 Jan; 44(1):36-40. PubMed ID: 26432184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]